Advanced search
1 file | 206.16 KB

Brief report: Smoking in systemic sclerosis : a longitudinal European Scleroderma Trials and Research group study

(2018) ARTHRITIS & RHEUMATOLOGY. 70(11). p.1829-1834
Author
Organization
Abstract
Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P < 0.001). The FEV1/FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.
Keywords
CIGARETTE-SMOKING, HISTORY, ULCERS, INDEX

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 206.16 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Jaeger, Veronika K, Gabriele Valentini, Eric Hachulla, Franco Cozzi, Oliver Distler, Paolo Airó, Laszlo Czirják, et al. 2018. “Brief Report: Smoking in Systemic Sclerosis : a Longitudinal European Scleroderma Trials and Research Group Study.” Arthritis & Rheumatology 70 (11): 1829–1834.
APA
Jaeger, V. K., Valentini, G., Hachulla, E., Cozzi, F., Distler, O., Airó, P., Czirják, L., et al. (2018). Brief report: Smoking in systemic sclerosis : a longitudinal European Scleroderma Trials and Research group study. ARTHRITIS & RHEUMATOLOGY, 70(11), 1829–1834.
Vancouver
1.
Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, et al. Brief report: Smoking in systemic sclerosis : a longitudinal European Scleroderma Trials and Research group study. ARTHRITIS & RHEUMATOLOGY. 2018;70(11):1829–34.
MLA
Jaeger, Veronika K et al. “Brief Report: Smoking in Systemic Sclerosis : a Longitudinal European Scleroderma Trials and Research Group Study.” ARTHRITIS & RHEUMATOLOGY 70.11 (2018): 1829–1834. Print.
@article{8600422,
  abstract     = {Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. 
Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. 
Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P < 0.001). The FEV1/FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. 
Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.},
  author       = {Jaeger, Veronika K and Valentini, Gabriele and Hachulla, Eric and Cozzi, Franco and Distler, Oliver and Airó, Paolo and Czirják, Laszlo and Allanore, Yannick and Siegert, Elise and Rosato, Edoardo and Matucci-Cerinic, Marco and Caimmi, Cristian and Henes, Jörg and Carreira, Patricia E and Smith, Vanessa and del Galdo, Francesco and Denton, Christopher P and Ullman, Susanne and De Langhe, Ellen and Riccieri, Valeria and Alegre-Sancho, Juan J and Rednic, Simona and Müller-Ladner, Ulf and Walker, Ulrich A},
  issn         = {2326-5191},
  journal      = {ARTHRITIS & RHEUMATOLOGY},
  keywords     = {CIGARETTE-SMOKING,HISTORY,ULCERS,INDEX},
  language     = {eng},
  number       = {11},
  pages        = {1829--1834},
  title        = {Brief report: Smoking in systemic sclerosis : a longitudinal European Scleroderma Trials and Research group study},
  url          = {http://dx.doi.org/10.1002/art.40557},
  volume       = {70},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: